These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8849398)

  • 1. Clinical observations with a new specific assay for bone alkaline phosphatase: a cross-sectional study in osteoporotic and pagetic subjects and a longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates.
    Pedrazzoni M; Alfano FS; Girasole G; Giuliani N; Fantuzzi M; Gatti C; Campanini C; Passeri M
    Calcif Tissue Int; 1996 Nov; 59(5):334-8. PubMed ID: 8849398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
    Garnero P; Delmas PD
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1046-53. PubMed ID: 8104954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women.
    Kress BC; Mizrahi IA; Armour KW; Marcus R; Emkey RD; Santora AC
    Clin Chem; 1999 Jul; 45(7):1009-17. PubMed ID: 10388477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation.
    Avbersek-Luznik I; Gmeiner Stopar T; Marc J
    Clin Chem Lab Med; 2007; 45(8):1014-8. PubMed ID: 17579570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase.
    Broyles DL; Nielsen RG; Bussett EM; Lu WD; Mizrahi IA; Nunnelly PA; Ngo TA; Noell J; Christenson RH; Kress BC
    Clin Chem; 1998 Oct; 44(10):2139-47. PubMed ID: 9761247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.
    Bergman A; Qureshi AR; Haarhaus M; Lindholm B; Barany P; Heimburger O; Stenvinkel P; Anderstam B
    J Nephrol; 2017 Apr; 30(2):255-262. PubMed ID: 26994005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of bone alkaline phosphatase in osteoporosis.
    Kyd PA; Vooght KD; Kerkhoff F; Thomas E; Fairney A
    Ann Clin Biochem; 1998 Nov; 35 ( Pt 6)():717-25. PubMed ID: 9838984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum bone formation marker correlation with improved osseointegration in osteoporotic rats treated with simvastatin.
    Du Z; Chen J; Yan F; Doan N; Ivanovski S; Xiao Y
    Clin Oral Implants Res; 2013 Apr; 24(4):422-7. PubMed ID: 22092686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women.
    Bruyere O; Collette J; Delmas P; Rouillon A; Roux C; Seidel L; Richy F; Reginster JY
    Maturitas; 2003 Apr; 44(4):259-65. PubMed ID: 12697366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease.
    Piovesan A; Berruti A; Torta M; Cannone R; Sperone P; Panero A; Gorzegno G; Termine A; Dogliotti L; Angeli A
    Calcif Tissue Int; 1997 Nov; 61(5):362-9. PubMed ID: 9351876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis.
    Gonnelli S; Cepollaro C; Pondrelli C; Martini S; Monaco R; Gennari C
    J Bone Miner Res; 1997 Apr; 12(4):624-31. PubMed ID: 9101374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
    Pedrazzoni M; Alfano FS; Gatti C; Fantuzzi M; Girasole G; Campanini C; Basini G; Passeri M
    Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Alkaline Phosphatase and Urine Hydroxyproline Assay in Pre and Postmenopausal Women in the State of Sikkim and its Correlation with Bone Mineral Density.
    Rai AD; Sherpa ML; Singh A; Thejaswi SG; Bhutia RD
    J Midlife Health; 2021; 12(4):304-309. PubMed ID: 35264838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
    Price RI; Gutteridge DH; Stuckey BG; Kent GN; Retallack RW; Prince RL; Bhagat CI; Johnston CA; Nicholson GC; Stewart GO
    J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
    Aonuma H; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
    Tohoku J Exp Med; 2009 Jul; 218(3):201-5. PubMed ID: 19561390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclical pamidronate infusions in postmenopausal osteoporosis.
    Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
    Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.